H.C. Wainwright Downgrades Terns Pharmaceuticals (TERN) to Neutral
H.C. Wainwright analyst Andrew Fein downgraded Terns Pharmaceuticals (NASDAQ: TERN) from Buy to Neutral.The analyst comments "What’s new? Merck (MRK ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)